Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma

NCT06405321 · tracked via the Priya Life Science China tracker

Sponsor

Guangxi Medical University

Phase

Observational

Started

2019-01-01

Last updated

2026-01-14

Condition(s) studied

Hepatocellular Carcinoma

Investigational drug(s) / intervention(s)

Conversion or neoadjuvant therapy.

Conversion or neoadjuvant therapy.: Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.

Study summary

This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Histologically or clinically confirmed diagnosis of HCC. * Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy. * Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1. * With Child-Pugh 5\~7 scores. Exclusion Criteria: * Concurrent with other malignancies within 5 years. * Incomplete medical data. * Follow-up time less than 3 months.

Primary outcome measure(s)

Overall survival — 1 year
1 year overall survival

Trial sites (1)

Facility	City	Region	Status
Jian-Hong Zhong	Nanning	China	Recruiting

More Guangxi Medical University trials in China

Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction Recruiting

AI Multimodal Model for Liver Cancer Diagnosis and Prognosis Active, not recruiting

Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer Recruiting

The Workplace-Based Hypertension Management Program Starting soon

Adjuvant TACE in HCC With High-risk Recurrence Factors Recruiting

Other trials for the same condition

Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid Active, not recruiting

Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma Recruiting

HAIC Compared With TACE in Huge Hepatocellular Carcinoma Recruiting

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma Recruiting

Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06405321 on ClinicalTrials.gov ↗ ← All trials in China